Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

November 18, 2010

Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin^® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain

Otsuka Pharmaceutical Co., Ltd. today announced that it has applied for regulatory approval in Japan for an additional indication of L-Cartin^® tablets (nonproprietary name: levocarnitine chloride) for carnitine deficiency, based on the evidences in the public domain.

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin^® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan